Biocept, Inc. (BIOCQ)

Biocept Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	25.86	61.25	27.46	5.53	3.25
Revenue Growth (YoY)	-57.78%	123.04%	396.71%	70.09%	-35.88%
Cost of Revenue	28.44	37.76	21.34	10.98	10.05
Gross Profit	-2.58	23.49	6.12	-5.45	-6.8
Selling, General & Admin	23.24	20.93	16.37	12.91	12.99
Research & Development	6.16	4.96	5.22	4.7	4.47
Operating Expenses	29.4	25.89	21.59	17.61	17.46
Operating Income	-31.98	-2.41	-15.47	-23.06	-24.26
Interest Expense	-0.32	-0.29	-0.24	-0.25	-0.31
Other Non Operating Income (Expenses)	0.09	-	-2.1	-1.83	-
Pretax Income	-32.21	-2.7	-17.81	-25.14	-24.57
Income Tax Expense	-0.13	0.13	-	-	0
Net Income	-32.09	-2.82	-17.81	-25.14	-24.57
Preferred Dividends & Other Adjustments	-	-	0	0.12	0.64
Net Income to Common	-32.09	-2.82	-17.81	-25.26	-25.21
Shares Outstanding (Basic)	1	0	0	0	-
Shares Outstanding (Diluted)	1	0	0	0	-
Shares Change (YoY)	14.74%	24.74%	473.32%	-	-
EPS (Basic)	-56.78	-5.73	-45.11	-366.78	-
EPS (Diluted)	-56.78	-5.73	-45.11	-366.90	-
Free Cash Flow	-14.1	2.12	-20.65	-23.78	-22.5
Free Cash Flow Per Share	-24.94	4.30	-52.31	-345.36	-
Gross Margin	-9.98%	38.34%	22.30%	-98.56%	-209.26%
Operating Margin	-123.69%	-3.93%	-56.33%	-417.05%	-746.35%
Profit Margin	-124.09%	-4.61%	-64.86%	-456.89%	-775.56%
Free Cash Flow Margin	-54.51%	3.46%	-75.21%	-430.21%	-692.26%
EBITDA	-30.33	-0.88	-14.38	-22.13	-23.46
EBITDA Margin	-117.29%	-1.44%	-52.38%	-	-
D&A For EBITDA	1.66	1.53	1.09	0.93	0.8
EBIT	-31.98	-2.41	-15.47	-23.06	-24.26
EBIT Margin	-123.69%	-3.93%	-56.33%	-	-

Updated Aug 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.